SequelSEC

biote Corp. BTMD

Medicinal Chemicals & Botanical Products · CIK 0001819253 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$44.23M
Fiscal year ended 2026-06-30
Operating income
-$3.51M
Fiscal year ended 2026-06-30
Free cash flow
-$3.73M
Fiscal year ended 2026-06-30

biote Corp. (BTMD) reported revenue of $44.23M and net income of -$6.56M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from biote Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Medicinal Chemicals & Botanical Products.

Income

biote Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$44.23M$44.94M$46.41M$47.96M$48.86M$48.99M$49.83M$51.38M$49.17M$46.80M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$3.51M$3.17M$6.83M$8.27M$10.76M$9.69M$2.77M$12.18M$6.23M$10.43M
Net income-$6.56M$2.28M$1.95M$8.19M$3.18M$13.72M$3.70M$10.70M-$7.09M-$4.16M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 28.63Mshares 36.00MUnavailableshares 36.71Mshares 31.74Mshares 36.95MUnavailableshares 32.26Mshares 33.07Mshares 34.62M
Pretax income-$7.13M$3.34M$5.60M$8.45M$6.08M$17.46M-$1.22M$15.86M-$10.30M-$3.32M
Income tax expense$296.00K$662.00K$2.99M-$765.00K$2.15M$1.62M-$4.70M$3.20M$73.00K$2.40M
Diluted EPS$-0.23$0.06Unavailable$0.22$0.10$0.37Unavailable$0.33$-0.21$-0.12
Selling, general & administrative$32.43M$27.79M$24.74M$26.15M$24.22M$26.69M$33.03M$23.92M$27.58M$22.92M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

biote Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$11.17M$5.32M$24.12M$28.05M$19.60M$41.70M$39.34M$38.22M$26.42M$78.79M
Total assets$101.70M$89.03M$107.61M$111.32M$104.80M$123.38M$122.37M$101.25M$92.90M$160.11M
Current assets$43.04M$36.36M$54.67M$57.12M$49.50M$68.68M$68.13M$69.98M$61.77M$114.36M
Total liabilities$159.89M$136.99M$158.01M$176.79M$183.64M$208.20M$224.57M$228.08M$234.55M$205.01M
Current liabilities$30.10M$28.23M$44.99M$56.31M$50.54M$48.47M$51.51M$46.51M$46.27M$24.06M
Total equity incl. NCI-$58.19M-$47.96M-$50.40M-$65.47M-$78.84M-$84.83M-$102.20M-$126.82M-$141.46M-$44.82M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$18.33M$19.88M$19.06M$16.45M$12.13M$13.45M$14.84M$16.20M$19.21M$18.92M
Accounts receivable$7.81M$7.40M$6.87M$7.97M$9.08M$7.76M$7.63M$8.49M$7.70M$8.02M
Goodwill$5.83M$5.83M$5.83M$5.83M$5.83M$5.83M$5.83M$5.52M$5.52M$5.52M
Long-term debt$118.38M$94.42M$95.78M$97.13M$98.49M$99.85M$101.20M$102.55M$103.91M$105.27M
Accounts payable$6.58M$8.24M$6.83M$4.36M$3.86M$3.34M$5.81M$4.37M$5.79M$4.20M

Cash flow

biote Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$1.18M$3.90M$7.57M$14.07M$7.09M$6.47M$12.37M$15.56M$9.95M$7.37M
Capital expenditures$2.56M$362.00K$1.08M$499.00K$1.81M$1.63M$1.67M$1.55M$2.51M$704.00K
Investing cash flow-$2.62M-$1.17M-$2.36M-$690.00K-$1.96M-$1.85M-$1.31M-$1.97M-$3.34M-$12.18M
Financing cash flow$9.65M-$21.54M-$9.13M-$4.94M-$27.23M-$2.26M-$9.93M-$1.77M-$58.97M-$5.41M
Net change in cash$5.85M-$18.80M-$3.92M$8.45M-$22.10M$2.36M$1.12M$11.81M-$52.37M-$10.22M
Stock-based compensation$1.97M$1.76M$2.20M$2.41M$2.19M$2.13M$1.89M$2.24M$2.84M$1.76M
Common dividends paid$616.00K$405.00K$138.00K$8.00K$887.00K$694.00K$88.00K$453.00K$4.12M$83.00K
Common share repurchases$4.79M$1.07M$0UnavailableUnavailableUnavailable$0$0$1.51M$4.09M
Depreciation & amortization$963.00K$980.00K$951.00K$952.00K$910.00K$857.00K$1.14M$810.00K$876.00K$750.00K

Derived

biote Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$3.73M$3.54M$6.49M$13.57M$5.28M$4.84M$10.70M$14.01M$7.44M$6.67M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-7.9%7.0%14.7%17.2%22.0%19.8%5.6%23.7%12.7%22.3%
FCF margin-8.4%7.9%14.0%28.3%10.8%9.9%21.5%27.3%15.1%14.2%
SBC / revenue4.5%3.9%4.7%5.0%4.5%4.3%3.8%4.4%5.8%3.8%
Current ratio1.43x1.29x1.22x1.01x0.98x1.42x1.32x1.50x1.34x4.75x
Revenue YoY growth-9.5%-8.3%-6.9%-6.7%-0.6%4.7%9.0%12.8%-0.2%4.4%
Net margin-14.8%5.1%4.2%17.1%6.5%28.0%7.4%20.8%-14.4%-8.9%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue5.8%0.8%2.3%1.0%3.7%3.3%3.4%3.0%5.1%1.5%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable19.8%53.3%-9.1%35.4%9.3%Unavailable20.2%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BTMD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.